Clinical Trials Logo

Acute Bleeding clinical trials

View clinical trials related to Acute Bleeding.

Filter by:
  • None
  • Page 1

NCT ID: NCT06019364 Enrolling by invitation - Blood Transfusion Clinical Trials

Transfusion of Whole Blood in Acute Bleeding

HEPEP
Start date: September 10, 2023
Phase:
Study type: Observational

Blood collected from blood donors is routinely divided into its different components, red blood cells, plasma and platelets. These components are stored under different storage conditions and their maximum storage time before transfusion is different. Platelets are stored at a maximum of 7 days and at a temperature of 22°C to best preserve their function. Research has been conduction on blood stored and transfused as whole blood (without separation into the various components), particularly in situations of acute trauma. Region Örebro län will therefore start transfusion of whole blood in such situations. The whole blood units will be stored at 4°C for a maximum of 14 days. This means that the platelets will be stored at a lower temperature than standard and for a longer time period. The research on how this will affect platelet function is limited. This project aims to determine how the patients are affected regarding coagulation, hemolysis, renal function, immunisation, transfusion reactions and the effect of substances released from the blood cells in the whole blood units during the storage period and if there is an impact on mortality.

NCT ID: NCT02885545 Withdrawn - Clinical trials for Chronic Kidney Disease

The Strategy to Prevent Hemorrhage Associated With Anticoagulation in Renal Disease Management (STOP HARM) Trial

STOP-HARM
Start date: September 2016
Phase: Phase 4
Study type: Interventional

Patients with severe chronic kidney disease (CKD) who develop atrial fibrillation are at high risk for stroke. The use of blood thinking medication in dialysis patients is controversial and warfarin carries a serious risk for major bleeding. The Watchman device may be an ideal therapy for this population as after implantation it allows for the discontinuation of blood thinners, thereby reducing the risk of bleeding.